ARTICLE SUMMARY:
Discussions about AI’s impact on healthcare often focus on drug discovery, healthcare system operational efficiencies, and clinical decision support for physicians. A conference organized by the New York Academy of Sciences and Mount Sinai Medical Center also included talks by executives from major AI companies NVIDIA and Microsoft on their research strategies, including important initiatives involving medical device manufacturers.
At a recent conference on adoption of artificial intelligence (AI) by healthcare systems, NVIDIA executive Raghav Mani cited a telling statistic: the US healthcare industry is adopting AI at three times the rate of other industry verticals, a speed that is counterintuitive, given healthcare’s historical conservative approach to new technology adoption.
The reasons are partly due to the urgency of unmet needs throughout the system, and partly because the technology is maturing to a point “where it can meaningfully address the pain points,” said Mani, who is NVIDIA’s director of digital health products (see Figure 1).
The conference, organized by the New York Academy of Sciences and the Mount Sinai Medical Center in New York, captured the status of AI adoption, its current bottlenecks, and predictions of its longer-term role in healthcare.
